Page 251 - 2021_07-Haematologica-web

Letters to the Editor
6. West AM, Kramer CM. Comprehensive cardiac magnetic resonance imaging. J Invasive Cardiol. 2009;21(7):339-345.
7. Gerber BL, Raman SV, Nayak K, et al. Myocardial first-pass perfu- sion cardiovascular magnetic resonance: history, theory, and current state of the art. J Cardiovasc Mag Reson. 2008;10(1):18.
8.Niss O, Taylor MD. Applications of cardiac magnetic resonance imaging in sickle cell disease. Blood Cells Mol Dis. 2017;67:126-134.
9. Hunold P, Schlosser T, Vogt FM, et al. Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease. AJR Am J Roentgenol. 2005;
184(5):1420-1426.
10. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of
myocardial infarction. J Am Coll Cardiol. 2018;72(18):2231-2264.
11. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell dis-
ease. Life expectancy and risk factors for early death. N Engl J Med.
1994;330(23):1639-1644.
12. James TN, Riddick L, Massing GK. Sickle cells and sudden death:
morphologic abnormalities of the cardiac conduction system. J Lab
Clin Med. 1994;124(4):507-520.
13.Samim A, Nugent L, Mehta PK, et al. Treatment of angina and
microvascular coronary dysfunction. Curr Treat Options
Cardiovasc Med. 2010;12(4):355-364.
14. Khalique Z, Pavlu J, Lefroy D, et al. Erythrocytapheresis in the pre-
vention of recurrent myocardial infarction in sickle cell disease. Am
J Hematol. 2010;85(1):91-91.
15. Sachdev V, Sidenko S, Wu MD, et al. Skeletal and myocardial
microvascular blood flow in hydroxycarbamide-treated patients with sickle cell disease. Br J Haematol. 2017;179(4):648-656.
haematologica | 2021; 106(7)
2021